The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 4 , Pages 969-975 , October 2003

Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

  • Robert Saeid Farivar, MD, PhD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Mass, USA
    • Dr Farivar is a recipient of an individual National Research Service Award (F32-HL6753902) from the National Institutes of Health.
    • ,
  • Lawrence H. Cohn, MD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Mass, USA
    • Corresponding Author InformationAddress for reprints: Lawrence H. Cohn, MD, Division of Cardiac Surgery, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA

Received 13 March 2003 ,Revised 14 April 2003 ,Accepted 21 April 2003.

References 

  1. Cohn LH, Collins JJ, Rizzo RJ, Adams DH, Couper GS, Aranki SF. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann Thorac Surg. 1998;66(suppl):S30–34
  2. Jamieson W, Burr L, Munro A, Miyagishima R. Carpentier-Edwards standard porcine bioprosthesis (a 21-year experience). Ann Thorac Surg. 1998;66(suppl):S40–S43
  3. Schoen FJ. Cardiac valve prostheses (review of clinical status and contemporary biomaterials issues). J Biomed Mater Res. 1987;21:91–117
  4. Mohler ER. Are atherosclerotic processes involved in aortic-valve calcification?. Lancet. 2000;356:524–525
  5. Demer LL. Cholesterol in vascular and valvular calcification. Circulation. 2001;104:1881–1883
  6. Pohle K, Maffert R, Ropers D, et al.  Progression of aortic valve calcification (association with coronary atherosclerosis and cardiovascular risk factors). Circulation. 2001;104:1927–1932
  7. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–1978
  8. Bild D, Folsom A, Lowe L, et al.  Prevalence and correlates of coronary calcification in black and white young adults (the coronary artery risk development in young adults (CARDIA) study). Arterioscler Thromb Vasc Biol. 2001;21:421–426
  9. Shavelle D, Takasu J, Budoff M, Mao S, Zhao X, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125–1126
  10. Pearlman A. Medical treatment of aortic stenosis (promising or wishful thinking). J Am Coll Cardiol. 2002;40:1731–1734
  11. O'Brien MF. What is the progression of aortic valve stenosis (bicuspid, congenital, acquired, degenerative)? Can this progression be modified by statin therapy? Is “prophylactic” AVR for mild AS indicated during CABG? Presented as an abstract at the American College of Cardiology, Hawaii, February 2003. American College of Cardiology; 2003
  12. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis (implications for secondary prevention). Circulation. 2000;101:2497–2502
  13. Jones EL, Weintraub WS, Craver JM, Guyton RM, Shen Y. Interaction of age and coronary disease after valve replacement (implication for valve selection). Ann Thorac Surg. 1994;58:378–385
  14. Kirklin JK, Smith D, Novick W, et al.  Long-term function of cryopreserved aortic homografts (a ten-year study). J Thorac Cardiovasc Surg. 1993;106:154–166
  15. Cleveland D, Williams W, Razzouk A, et al.  Failure of cryopreserved homograft valved conduits in the pulmonary circulation. Circulation. 1992;86(suppl):II150–153
  16. Miller D, Stinson E, Oyer P, et al.  The durability of porcine xenograft valves and conduits in children. Circulation. 1982;66(suppl):I172–185
  17. Bellamy M, Pellika P, Klarish K, et al.  Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723–1730
  18. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–2209
  19. Aronow W, Ahn C, Kronzon I, Goldman M. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–695
  20. Vyavahare NR, Jones PL, Hirsch D, Schoen FJ, Levy RJ. Prevention of glutaraldehyde-fixed bioprosthetic heart valve calcification by alcohol pretreatment (further mechanistic studies). J Heart Valve Dis. 2000;9:561–566
  21. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218–1222
  22. Chin H, Harrison E, Blankenhorn D, Moacanin J. Lipids in silicone rubber valve prostheses after human implantation. Circulation. 1971;43/44(suppl):I51–56
  23. Ferrans VJ, McManus B, Roberts WC. Cholesteryl ester crystals in a porcine aortic valvular bioprosthesis implanted for eight years. Chest. 1983;83:698–701

PII: S0022-5223(03)00708-6

doi: 10.1016/S0022-5223(03)00708-6

The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 4 , Pages 969-975 , October 2003

Article Tools

* Image Usage & Resolution